PIK3CA Cooperates with Other Phosphatidylinositol 3′-Kinase Pathway Mutations to Effect Oncogenic Transformation
Katsutoshi Oda(The University of Tokyo), Frank McCormick(Frederick National Laboratory for Cancer Research), Pablo Rodriguez‐Viciana(University College London), Hiroyuki Kuramoto(Kitasato University), Jennifer Okada, Kevan M. Shokat(Howard Hughes Medical Institute), David Stokoe(Enzo Life Sciences (United States)), Luika Timmerman(University of California, San Francisco), Yuji Taketani(The University of Tokyo), Keiko Shoji(The University of Tokyo), Zachary A. Knight(Howard Hughes Medical Institute)
Cited by 193
Related Papers
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
|Nature|2013|2.5k
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
|Nature|2010|1.8k
Molecular Determinants of the Response of Glioblastomas to EGFR Kinase Inhibitors
|New England Journal of Medicine|2005|1.4k
IRE1 Signaling Affects Cell Fate During the Unfolded Protein Response
|Science|2007|1.4k